SG10201707598QA - C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency - Google Patents
C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficencyInfo
- Publication number
- SG10201707598QA SG10201707598QA SG10201707598QA SG10201707598QA SG10201707598QA SG 10201707598Q A SG10201707598Q A SG 10201707598QA SG 10201707598Q A SG10201707598Q A SG 10201707598QA SG 10201707598Q A SG10201707598Q A SG 10201707598QA SG 10201707598Q A SG10201707598Q A SG 10201707598QA
- Authority
- SG
- Singapore
- Prior art keywords
- deficency
- prevention
- treatment
- methods
- disorders associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791399P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201707598QA true SG10201707598QA (en) | 2017-10-30 |
Family
ID=51538486
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201707598QA SG10201707598QA (en) | 2013-03-15 | 2014-03-17 | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency |
| SG11201507616VA SG11201507616VA (en) | 2013-03-15 | 2014-03-17 | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507616VA SG11201507616VA (en) | 2013-03-15 | 2014-03-17 | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency |
Country Status (30)
| Country | Link |
|---|---|
| US (9) | US9616111B2 (hr) |
| EP (3) | EP2968434B1 (hr) |
| JP (9) | JP6184581B2 (hr) |
| KR (4) | KR102430453B1 (hr) |
| CN (2) | CN111529708A (hr) |
| AU (3) | AU2014232912A1 (hr) |
| BR (1) | BR112015023207A8 (hr) |
| CA (2) | CA2904543C (hr) |
| CY (2) | CY1119419T1 (hr) |
| DE (1) | DE202014011208U1 (hr) |
| DK (2) | DK2968434T3 (hr) |
| EA (1) | EA201591278A1 (hr) |
| ES (2) | ES2713004T3 (hr) |
| GB (1) | GB2530921B (hr) |
| HK (2) | HK1220403A1 (hr) |
| HR (2) | HRP20171269T1 (hr) |
| HU (2) | HUE041837T2 (hr) |
| IL (2) | IL241549B (hr) |
| LT (2) | LT2968434T (hr) |
| ME (2) | ME03326B (hr) |
| MX (3) | MX2020004724A (hr) |
| NZ (2) | NZ710730A (hr) |
| PL (2) | PL2968434T3 (hr) |
| PT (2) | PT3290046T (hr) |
| RS (2) | RS58351B1 (hr) |
| SG (2) | SG10201707598QA (hr) |
| SI (2) | SI3290046T1 (hr) |
| TR (1) | TR201900319T4 (hr) |
| WO (1) | WO2014145519A2 (hr) |
| ZA (3) | ZA201507604B (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ710730A (en) | 2013-03-15 | 2021-07-30 | Viropharma Biologics Llc | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency |
| KR102312817B1 (ko) * | 2013-11-22 | 2021-10-13 | 다케다 야쿠힌 고교 가부시키가이샤 | C1-에스테라제 억제제를 사용한 장기 이식 환자에서의 항체-매개성 거부반응의 치료 방법 |
| RU2017132449A (ru) * | 2015-02-20 | 2019-03-21 | Цсл Беринг Гмбх | Фармацевтические композиции ингибитора c1-эстеразы |
| CN108025047B (zh) * | 2015-05-28 | 2021-11-19 | 康奈尔大学 | 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法 |
| JP7189767B2 (ja) * | 2015-11-19 | 2022-12-14 | 武田薬品工業株式会社 | 組換えヒトｃ１エステラーゼインヒビター及びその使用 |
| EP3493832A1 (en) | 2016-08-05 | 2019-06-12 | CSL Behring GmbH | Pharmaceutical formulations of c1 esterase inhibitor |
| JP2019534240A (ja) * | 2016-08-23 | 2019-11-28 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | Ｃ１エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法 |
| MX2019013711A (es) * | 2017-05-16 | 2020-01-30 | Octapharma Ag | Preparacion de inhibidor de c1 esterasa. |
| WO2019166572A1 (en) | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
| BR112020017626A2 (pt) | 2018-02-28 | 2020-12-22 | Pharming Intellectual Property B.V. | Tratamento e prevenção de pré-eclâmpsia |
| CN112584843A (zh) | 2018-06-22 | 2021-03-30 | 顺天生化股份有限公司 | 用于诱发感染性免疫耐受的组合物 |
| CA3104797A1 (en) | 2018-06-22 | 2019-12-26 | Junten Bio Co., Ltd. | Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte |
| KR20210025062A (ko) | 2018-06-22 | 2021-03-08 | 가부시키가이샤 준텐 바이오 | 면역 관용을 유도하는 항체, 유도된 림프구, 또한 유도된 림프구를 이용하는 세포 치료제 치료법 |
| JPWO2021124793A1 (hr) * | 2019-12-16 | 2021-06-24 | ||
| EP3895726A1 (en) | 2020-04-17 | 2021-10-20 | Pharming Intellectual Property BV | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress |
| JP2024525084A (ja) | 2021-07-09 | 2024-07-09 | ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． | Ｃ１エステラーゼ阻害剤によるウイルス感染関連症状の治療 |
| KR20230046146A (ko) | 2021-09-29 | 2023-04-05 | 주식회사 엘지에너지솔루션 | 배터리 제어 시스템 및 방법 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304482A (en) | 1989-03-06 | 1994-04-19 | The Board Of Regents Of The University Of Texas System | Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors |
| WO1992022320A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | C1 inhibitor variants and treating inflammatory response with c1 inhibitor |
| ES2171465T3 (es) * | 1993-09-01 | 2002-09-16 | Sanquin Bloedvoorziening | Inhibidor de la esterasa de c1 para reducir lesiones de miocardio durante un infarto de miocardio agudo. |
| JP2000507204A (ja) | 1995-12-18 | 2000-06-13 | ステイヒテイング・サンキン・ブロードボールジーニング | Ｃ１―インヒビターの補体及び血液凝固阻害特性の強化 |
| AT409336B (de) * | 1999-12-22 | 2002-07-25 | Baxter Ag | Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung |
| DE60132169T2 (de) | 2000-01-31 | 2008-12-11 | Pharming Intellectual Property Bv | Humaner c1 inhibitor hergestellt in der milch transgener säugetiere |
| US7067713B2 (en) * | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| SI1324776T2 (en) | 2000-10-12 | 2018-06-29 | Genentech, Inc. | Concentrated protein formulations with reduced viscosity |
| DE10112617A1 (de) | 2001-03-14 | 2002-10-02 | Aventis Behring Gmbh | Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren |
| WO2004034971A2 (en) | 2002-09-25 | 2004-04-29 | The Center For Blood Research, Inc. | Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof |
| WO2004110356A2 (en) | 2003-05-15 | 2004-12-23 | Cbr Institute For Biomedical Research, Inc. | Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity |
| PL1626736T3 (pl) | 2003-05-16 | 2021-05-04 | Pharming Intellectual Property B.V. | Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego |
| US20060233776A1 (en) | 2003-08-19 | 2006-10-19 | Norbert Heimburger | C1-inh as a drug for treating viruses pathogenic to humans |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| CA2654440C (en) | 2005-06-06 | 2013-09-03 | Girish J. Kotwal | Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury |
| WO2007047995A2 (en) | 2005-10-21 | 2007-04-26 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
| ATE516043T1 (de) | 2005-12-21 | 2011-07-15 | Pharming Intellectual Pty Bv | Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden |
| ES2369522T3 (es) * | 2005-12-21 | 2011-12-01 | Pharming Intellectual Property B.V. | Uso de un inhibidor c1 para la prevención de lesiones por isquemia-reperfusión. |
| US7837992B2 (en) | 2006-06-22 | 2010-11-23 | Beth Israel Deaconess Medical Center | C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis |
| EP2109457B1 (en) | 2007-02-12 | 2016-01-06 | CSL Behring GmbH | Therapeutic application of kazal-type serine protease inhibitors |
| CA2707483A1 (en) | 2007-11-30 | 2009-06-11 | Wolfgang Fraunhofer | Protein formulations and methods of making same |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| US20100143325A1 (en) | 2008-12-09 | 2010-06-10 | Vascular Laboratory, Inc. | Composition And Methods Involving Thrombolytic Agents |
| JP5871798B2 (ja) | 2009-07-02 | 2016-03-01 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 肝再生を刺激する方法 |
| RU2600876C2 (ru) | 2009-10-16 | 2016-10-27 | Омерос Корпорейшен | Способ лечения диссеминированного внутрисосудистого свертывания крови путем ингибирования masp-2 зависимой активации комплемента |
| WO2011107591A1 (en) | 2010-03-05 | 2011-09-09 | Rigshospitalet | Chimeric inhibitor molecules of complement activation |
| US20130085111A1 (en) * | 2010-03-18 | 2013-04-04 | Thrombolytic Science, Llc | Production of human c1 inhibitor in human cells |
| WO2013013017A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics |
| CN104010656B (zh) | 2011-09-24 | 2016-02-24 | 德国杰特贝林生物制品有限公司 | 使用免疫球蛋白和c1-抑制剂的联合疗法 |
| CA2858984C (en) | 2011-12-22 | 2021-01-05 | Csl Behring Gmbh | Use of c1-inhibitor for the treatment of secondary edema of the central nervous system |
| WO2013138730A1 (en) | 2012-03-16 | 2013-09-19 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of c1-inhibitors |
| US20160033511A1 (en) | 2013-03-13 | 2016-02-04 | Creatics Llc | Methods and compositions for detecting pancreatic cancer |
| NZ710730A (en) * | 2013-03-15 | 2021-07-30 | Viropharma Biologics Llc | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency |
-
2014
- 2014-03-17 NZ NZ710730A patent/NZ710730A/en unknown
- 2014-03-17 SI SI201431032T patent/SI3290046T1/sl unknown
- 2014-03-17 ES ES17177676T patent/ES2713004T3/es active Active
- 2014-03-17 EP EP14762343.3A patent/EP2968434B1/en not_active Revoked
- 2014-03-17 RS RS20190198A patent/RS58351B1/sr unknown
- 2014-03-17 SG SG10201707598QA patent/SG10201707598QA/en unknown
- 2014-03-17 LT LTEP14762343.3T patent/LT2968434T/lt unknown
- 2014-03-17 ME MEP-2019-45A patent/ME03326B/me unknown
- 2014-03-17 ES ES14762343.3T patent/ES2639833T3/es active Active
- 2014-03-17 CN CN202010362851.6A patent/CN111529708A/zh active Pending
- 2014-03-17 DE DE202014011208.8U patent/DE202014011208U1/de not_active Expired - Lifetime
- 2014-03-17 GB GB1519921.9A patent/GB2530921B/en active Active
- 2014-03-17 EA EA201591278A patent/EA201591278A1/ru unknown
- 2014-03-17 CA CA2904543A patent/CA2904543C/en active Active
- 2014-03-17 DK DK14762343.3T patent/DK2968434T3/en active
- 2014-03-17 SI SI201430368T patent/SI2968434T1/sl unknown
- 2014-03-17 EP EP17177676.8A patent/EP3290046B1/en active Active
- 2014-03-17 NZ NZ751555A patent/NZ751555A/en unknown
- 2014-03-17 PL PL14762343T patent/PL2968434T3/pl unknown
- 2014-03-17 TR TR2019/00319T patent/TR201900319T4/tr unknown
- 2014-03-17 LT LTEP17177676.8T patent/LT3290046T/lt unknown
- 2014-03-17 CN CN201480014712.7A patent/CN105517559A/zh active Pending
- 2014-03-17 PT PT17177676T patent/PT3290046T/pt unknown
- 2014-03-17 KR KR1020217033628A patent/KR102430453B1/ko active IP Right Grant
- 2014-03-17 DK DK17177676.8T patent/DK3290046T3/en active
- 2014-03-17 KR KR1020217004777A patent/KR20210021146A/ko not_active IP Right Cessation
- 2014-03-17 RS RS20170802A patent/RS56285B1/sr unknown
- 2014-03-17 PL PL17177676T patent/PL3290046T3/pl unknown
- 2014-03-17 BR BR112015023207A patent/BR112015023207A8/pt not_active Application Discontinuation
- 2014-03-17 PT PT147623433T patent/PT2968434T/pt unknown
- 2014-03-17 HU HUE17177676A patent/HUE041837T2/hu unknown
- 2014-03-17 SG SG11201507616VA patent/SG11201507616VA/en unknown
- 2014-03-17 CA CA3054718A patent/CA3054718A1/en not_active Abandoned
- 2014-03-17 KR KR1020157022897A patent/KR20150135242A/ko active Application Filing
- 2014-03-17 ME MEP-2017-182A patent/ME02865B/me unknown
- 2014-03-17 WO PCT/US2014/030309 patent/WO2014145519A2/en active Application Filing
- 2014-03-17 MX MX2020004724A patent/MX2020004724A/es unknown
- 2014-03-17 KR KR1020227016244A patent/KR102579789B1/ko active IP Right Grant
- 2014-03-17 EP EP18206413.9A patent/EP3508213A1/en active Pending
- 2014-03-17 HU HUE14762343A patent/HUE036224T2/hu unknown
- 2014-03-17 AU AU2014232912A patent/AU2014232912A1/en not_active Abandoned
- 2014-03-17 JP JP2016503371A patent/JP6184581B2/ja active Active
- 2014-03-17 MX MX2015011281A patent/MX2015011281A/es active IP Right Grant
-
2015
- 2015-08-28 MX MX2021011946A patent/MX2021011946A/es unknown
- 2015-09-10 IL IL241549A patent/IL241549B/en active IP Right Grant
- 2015-09-15 US US14/855,168 patent/US9616111B2/en active Active
- 2015-10-13 ZA ZA2015/07604A patent/ZA201507604B/en unknown
-
2016
- 2016-07-19 HK HK16108590.9A patent/HK1220403A1/zh unknown
-
2017
- 2017-01-20 US US15/411,744 patent/US20170224788A1/en not_active Abandoned
- 2017-03-16 JP JP2017051361A patent/JP6422520B2/ja active Active
- 2017-08-18 HR HRP20171269TT patent/HRP20171269T1/hr unknown
- 2017-09-12 CY CY20171100961T patent/CY1119419T1/el unknown
- 2017-10-12 ZA ZA2017/06929A patent/ZA201706929B/en unknown
- 2017-12-11 US US15/837,969 patent/US10201595B2/en active Active
- 2017-12-11 US US15/837,677 patent/US10080788B2/en active Active
- 2017-12-11 US US15/837,693 patent/US10105423B2/en active Active
- 2017-12-11 US US15/837,938 patent/US10130690B2/en active Active
-
2018
- 2018-04-06 JP JP2018073689A patent/JP6473534B2/ja active Active
- 2018-04-06 JP JP2018073691A patent/JP6473536B2/ja active Active
- 2018-04-06 JP JP2018073690A patent/JP6473535B2/ja active Active
- 2018-08-02 US US16/053,457 patent/US11534482B2/en active Active
- 2018-08-10 HK HK18110262.0A patent/HK1250912B/zh unknown
- 2018-09-05 US US16/122,015 patent/US20190160158A1/en not_active Abandoned
- 2018-09-17 AU AU2018229558A patent/AU2018229558B2/en active Active
- 2018-10-12 ZA ZA2018/06793A patent/ZA201806793B/en unknown
-
2019
- 2019-01-25 JP JP2019011082A patent/JP6877471B2/ja active Active
- 2019-01-25 JP JP2019011079A patent/JP6877470B2/ja active Active
- 2019-01-25 JP JP2019011084A patent/JP6877472B2/ja active Active
- 2019-02-11 HR HRP20190270TT patent/HRP20190270T1/hr unknown
- 2019-03-15 CY CY20191100308T patent/CY1121653T1/el unknown
- 2019-10-02 US US16/591,184 patent/US11364288B2/en active Active
-
2020
- 2020-05-15 AU AU2020203183A patent/AU2020203183B2/en active Active
- 2020-07-19 IL IL276153A patent/IL276153B/en unknown
-
2021
- 2021-03-02 JP JP2021032716A patent/JP2021088599A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190270T1 (hr) | C1-inh pripravci i postupci za prevenciju i liječenje poremećaja povezanih s nedostatkom inhibitora c1 esteraze | |
| HK1210957A1 (en) | Effluz inhibitor compositions and methods of treatment using the same | |
| EP2968318A4 (en) | ANTI-PCSK9 COMPOUNDS AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASES | |
| EP3182989A4 (en) | Methods and compositions for the prevention and treatment of disease | |
| EP2961420A4 (en) | METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING BARTH SYNDROME | |
| IL244622A0 (en) | Preparations for the treatment of hypertension and/or fibrosis | |
| HK1220374A1 (zh) | 用於治療碳氧血紅蛋白血症的組合物和方法 | |
| IL244621A (en) | Preparations for the treatment of hypertension and / or fibrosis | |
| EP2964750A4 (en) | METHOD AND COMPOSITIONS FOR TREATING AND / OR PREVENTING TYPE-1 DIABETES | |
| HK1216721A1 (zh) | 治療肝臟疾病或病狀的用途和方法 | |
| EP2852569A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| EP3068431A4 (en) | Methods and compositions for the treatment of hcmv | |
| EP3071231A4 (en) | Compositions and methods for prophylaxis and/or therapy of disorders that correlate with dennd1a variant 2 | |
| EP3225237A4 (en) | Fatty acid amides for the prevention and/or treatment of steatohepatitis | |
| AU2013904048A0 (en) | Compositions and methods for the prevention and/or treatment of neurogenic inflammation and/or infla |